INTRODUCTION
============

Microsatellite is a tandem array of short stretches of nucleotide sequences, usually repeated between 15 and 30 times^[@b1-kjim-12-2-144-5],[@b2-kjim-12-2-144-5])^. These regions of genome tend to be polymorphic or variable among individuals. Recently, abnormalities of such repeats have been implicated in the genesis of hereditary non-polyposis colorectal cancer (HNPCC). In HNPCC kindreds, linkage to the marker D2S123 on chromosome 2p was reported, and it was simultaneously noted that instability of the microsatellite repeat number was present in microsatellites scattered throughout the genome^[@b3-kjim-12-2-144-5],[@b4-kjim-12-2-144-5])^. It was suggested that the mutation affecting DNA replication or repair predisposed to replication errors. Candidate gene of mismatch repair in gene *hMSH*2 was identified and shown to be a DNA mismatch binding protein^[@b5-kjim-12-2-144-5],[@b6-kjim-12-2-144-5])^. Subsequently, additional mismatch repair genes were shown to be involved in the pathogenesis of HNPCC, comprising *hMLH*1, *hPMS*1, and *hPM*2^[@b7-kjim-12-2-144-5],[@b8-kjim-12-2-144-5])^. Analysis of sporadic tumors belonging to the HNPCC spectrum (colorectal carcinoma, endometrial carcinoma and gastric carcinoma) revealed a significant proportion of cases with multiple replication errors, as in HNPCC cases^[@b9-kjim-12-2-144-5])^. In contrast, other sporadic tumors (lung, breast, testis, CNS tumors and soft tissue sarcomas) showed microsatellite instability (MI) as a rare event^[@b10-kjim-12-2-144-5])^. Recent reports show that cases of small cell carcinoma of the lung, cases with multiple primary tumors and late stage chronic myelocytic leukemia may be associated with replication error (RER)-positive phenotype^[@b11-kjim-12-2-144-5]--[@b13-kjim-12-2-144-5])^. Presumably, it has undergone a germ line mutation of mismatch repair genes in HNPCC; similarly somatic mutations of mismatch repair genes are presumed to have occurred in the tumors of some sporadic colon cancer^[@b14-kjim-12-2-144-5])^.

Gastric adenocarcinoma is one of the most common malignancies in the world, especially in Korea. Although the molecular basis of the development of gastric carcinoma remains unclear, there have been many attempts to apply the same analysis which has been effective in identifying the oncogenesis of colon cancer^[@b15-kjim-12-2-144-5],[@b16-kjim-12-2-144-5])^. However, little information is available regarding RER-positive phenotype in gastric carcinomas, particularly in terms of age of onset (gastric carcinoma of the young vs. elderly patient) and other pathologic features such as histologic types, degree of differentiation, location, and stage of the carcinoma. Gastric carcinoma of the young adult is characterized by mostly diffuse (by Lauren's criteria^[@b17-kjim-12-2-144-5])^ or signet-ring cell type (by WHO criteria^[@b18-kjim-12-2-144-5])^, poorly differentiated adenocarcinoma without adjacent intestinal metaplasia, and high incidence of family history of gastric carcinoma^[@b19-kjim-12-2-144-5]--[@b21-kjim-12-2-144-5])^. In order to obtain a better understanding of the molecular mechanism of gastric carcinogenesis, microsatellite instability was examined at 6 gene loci in 77 gastric carcinomas (40 cases of young patients and 37 cases of elderly patients).

MATERIALS AND METHODS
=====================

1. Materials
------------

Forty cases of subtotal or total gastrectomy specimens received at the Department of Pathology of Chonnam University Hospital (69 cases) and Presbyterian Medical Center (8 cases), which were diagnosed as primary adenocarcinoma of stomach in the interval of January 1, 1990 to May 1, 1996, were selected. The adenocarcinomas were classified according to the WHO criteria^[@b18-kjim-12-2-144-5])^, and clinicopathological data were collected from the review of medical records ([Table 1](#t1-kjim-12-2-144-5){ref-type="table"}). Males were 42 cases, and females were 35 cases. Tubular adenocarcinoma was 36, signet-ring cell type was 36 and mucinous type was 5 cases; well differentiated adenocarcinoma was 6, moderately differentiated was 21 and poorly differentiated was 50 cases. Four cases were located in the upper third of the stomach (cardia and fundus), 25 cases in the middle third (body) and 30 cases in the lower third (antrum and pylorus). Twelve cases were located in two different areas, and 6 cases were undetermined. Stage Ia was 13 cases, Ib 9, II 13, IIIa 13, IIIb 5, and IV 18. Stages were undetermined in 6 cases.

2. DNA isolation from the tissue
--------------------------------

A hematoxylin-eosin stained tissue section from each block was used to determine the area of highest tumor cellularity for DNA preparation. One or more tissue plugs were then removed from each block, minced with a razor blade and deparaffinized with a series of rinses in xylene and ethanol. The tissue was digested completely in TE buffer (pH 8.0), containing 400 μg/ml of proteinase K replenished daily and 0.5% sodium dodecyl sulfate, for 3--4 days at 54°C. Following a standard series of phenol, phenol/chloroform and chloroform extractions, the DNA was ethanol-precipitated, washed in 70% ethanol, resuspended in TE buffer (pH 8.0) and stored at −20°C.

3. PCR analysis at microsatellite loci
--------------------------------------

The primers used to examine the microsatellite loci were: D2S71, D2S119 (AFM077yb7)^[@b22-kjim-12-2-144-5])^, D3S1067^[@b23-kjim-12-2-144-5])^, D6S87 (MFD47)^[@b24-kjim-12-2-144-5])^, D8S87 (MFD39)^[@b25-kjim-12-2-144-5])^, and D11S905 (AFM105xb10)^[@b22-kjim-12-2-144-5])^. The PCR was performed in 10*μ*l volumes of a mixture containing 1x PCR buffer \[10mmol Tris-HCI, pH 8.8, 1.5mmol MgCl~2~, 50 mmol KCI, 0.1% Triton X-100\], 10pmol of unlabeled primer and 5pmol of labeled primer with \[γ-32p\]ATP(\>5,000ci/mmol), 50ng DNA, 0.1 units Taq DNA polymerase, 125*μ*mol of each deoxynucleotide. Reaction mixtures were heated to 95°C for 5 min and cycled 32 times; each cycle consisted of 1 min at 94°C, 1 min at 52--58°C, 1 min at 72°C for strand elongation. After that, heated for 10 min at 72°C for the final elongation using a PCR machine (Model 480, Perkin Elmer Cetus, Norwalk, CT, USA). Following PCR, 3*μ*l of reaction product was denatured and then electrophoresed in 6% polyacrylamide gels containing 8 mol urea. After electrophoresis, the gels were exposed to X-ray film for 3--6 h at −70°C.

4. Interpretation of PCR results
--------------------------------

Microsatellite instability (MI) was evident when the tumor DNAs gained new bands compared to their normal counterparts ([Fig. 1A, B](#f1-kjim-12-2-144-5){ref-type="fig"}). If at least one locus revealed MI, the case was regarded as RER-positive ([Table 2](#t2-kjim-12-2-144-5){ref-type="table"}). Deletion of band (loss of heterozygosity of microsatellite allele) was not considered to be a microsatellite alteration in the present study.

RESULTS
=======

[Table 2](#t2-kjim-12-2-144-5){ref-type="table"} summarizes results of PCR analyses in 40 cases of the gastric carcinoma in young adult and 37 cases in elderly. [Fig. 1A](#f1-kjim-12-2-144-5){ref-type="fig"} shows typical MI of young adult (J21) and [Fig. 1B](#f1-kjim-12-2-144-5){ref-type="fig"} reveals heterozygosity (O28) and MI (O29) from elderly patients.

Out of 77 cases of gastric carcinoma, 17 cases (22.1%) were RER-positive and 60 cases (77.9%) were RER-negative. Nine cases (22.5%) out of 40 young adult cases were RER-positive and 8 (21.6%) out of 37 elderly patients were RER-positive ([Table 3A](#t3-kjim-12-2-144-5){ref-type="table"}). Seven (16.7%) out of 42 male cases revealed RER-positive phenotype, and 10 (28.6%) out of 35 female cases showed RER-positive phenotype. There was no difference in RER-positivity between the male and female patients by logistic regression analysis ([Table 3B](#t4-kjim-12-2-144-5){ref-type="table"}). Ten (27.8%) out of 36 tubular type, 6 (16.7%) out of 36 signet-ring cell carcinoma and 1 (20.0%) out of 5 mucinous carcinoma were RER-positive phenotype ([Table 3C](#t5-kjim-12-2-144-5){ref-type="table"}).

One (16.7%) out of 6 well differentiated carcinoma was RER-positive, whereas 28.6% (6/21) of moderately differentiated carcinoma and 20.0% (10/50) of poorly differentiated carcinoma were RER-positive ([Table 3D](#t6-kjim-12-2-144-5){ref-type="table"}). Moderately differentiated carcinoma revealed higher frequency of RER-positive phenotypes than well differentiated carcinoma (p\<0.01; by logistic regression analysis).

None of the tumors located in the upper third of the stomach (cardia and fundus) were RER-positive, while 16.0% (4/25) of the tumors located in the middle third (body) and 26.7% (8/30) of the tumors located in the lower third (antrum and pylorus) was RER-positive. The frequency of RER-positive cases arising from the middle (p\<0.001) and lower third (p\<0.0001) of the stomach was significantly higher than the tumor arising from the upper third (by logistic regression analysis) ([Table 3E](#t7-kjim-12-2-144-5){ref-type="table"}).

Percentage of RER-positive cases was 15.4% (2/13) in stage IA, 11.1% (1/9) in stage IB, 7.7% (1/13) in stage II, 53.8% (7/13) in stage IIIA, 0% (0/5) in stage IIIB and 22.2% (4/18) in stage IV, respectively, by logistic regression analysis ([Table 3F](#t8-kjim-12-2-144-5){ref-type="table"}).

DISCUSSION
==========

It has been demonstrated that the expression of several oncogenes and the mutation of tumor suppressor genes may vary according to histologic types of gastric carcinoma and affect the biologic behavior of gastric carcinoma^[@b26-kjim-12-2-144-5],[@b27-kjim-12-2-144-5])^. Recently, RER-positive phenotypes have also occurred in sporadic gastric carcinoma and played a role in tumor progression. The frequency of RER-positive phenotype ranges from 15% to 38.5%^[@b28-kjim-12-2-144-5]--[@b32-kjim-12-2-144-5])^. The frequency of RER-positive phenotype of this study was 22.1%, when six chromosomal loci were examined. This suggests that RER-positive phenotype is important in some portion of gastric carcinogenesis.

Gastric carcinoma of the young adult is characterized by mostly diffuse (by Lauren's criteria^[@b17-kjim-12-2-144-5])^ or signet--ring cell type (by WHO criteria^[@b18-kjim-12-2-144-5])^, poorly differentiated adenocarcinoma without adjacent intestinal metaplasia and high incidence of family history of gastric carcinoma^[@b19-kjim-12-2-144-5]--[@b21-kjim-12-2-144-5])^. In the present study, the frequency of RER-positive phenotype in young patients was 22.5% compared to the 21.6% in elderly patients. When the other factors (such as sex, histologic type, degree of differentiation, location and stage) are considered, there is no significant difference of RER-positive phenotype between the two groups.

Tumors arising from the middle or lower third of the stomach revealed higher frequency of RER-positive phenotype than the tumors from the upper third (cardia and fundus). This finding supports the hypothesis that instability is tissue specific, as proximal colon carcinoma reveals higher frequency of RER-positive phenotype than distal colon carcinomas^[@b33-kjim-12-2-144-5],[@b34-kjim-12-2-144-5])^. RER-positive frequency was not affected by the histologic types, although tubular type and signet-ring cell carcinomas reveal relatively high frequency of RER-positivity compared with mucinous type. Moderately differentiated carcinoma revealed higher frequency of RER-positivity compared to the well differentiated carcinoma. Han et al^[@b28-kjim-12-2-144-5])^ reported that poorly differentiated carcinoma reveal a higher frequency of RER-positive phenotype than well differentiated one.

The result reveals that there is no difference of RER-positive phenotypes in the tumors of different stages. Even the carcinomas confined in the lamina propria (stage Ia) reveal 15.5% (2 out of 13 cases) RER-positive phenotype. Palmirotta et al.^[@b35-kjim-12-2-144-5])^ found that 50% of early gastric carcinomas are RER-positive when they analyzed at 11 microsatellite markers. Semba et al.^[@b36-kjim-12-2-144-5])^ found RER-positive phenotypes in 33% of mucosa of intestinal metaplasia, 42% of gastric adenoma and 33% of gastric carcinoma. These findings suggest that RER-positive phenotype would occur at the early stage of gastric carcinogenesis. Conversely, Chong et al.^[@b30-kjim-12-2-144-5])^ reported that frequency of RER-positive phenotype is significantly higher in advanced gastric carcinoma than in early gastric carcinoma (33.3% vs. 12.0%).

In conclusion, RER-positive phenotype occurs frequently in gastric carcinoma, and is tissue specific. But, there is no difference in RER-positive phenotypes between the young and elderly gastric carcinoma patients. The acquisition of RER-positive phenotype might be an early event in gastric carcinogenesis.

![Analysis of genetic instability in paired normal (N) and tumor (T) DNA at loci D2S71 of J21 patient (A), and D8S87 of O29 and O28 patients (B). At tumor DNAs, abnormal patterns indicating expansion are shown at each microsatelite locus. Normal alleles appear as major bands with their ladders. Patient numbers are shown above the lanes.\
MI(+); microsatellite-positive, MI(−); microsatellite-negative](kjim-12-2-144-5f1){#f1-kjim-12-2-144-5}

###### 

Clinicopathologic Data of the Gastric Carcinoma

  Number   Age   Sex   Type           Grade   Location     Stage
  -------- ----- ----- -------------- ------- ------------ -------
  J01      32    F     signet--ring   PD      MIDDLE 1/3   IA
  J02      27    M     tubular        PD      COMBINED     IV
  J03      33    F     signet--ring   PD      MIDDLE 1/3   IA
  J04      31    M     signet--ring   PD      MIDDLE 1/3   IIIA
  J05      28    M     signet--ring   PD      MIDDLE 1/3   IA
  J06      28    M     signet--ring   PD      COMBINED     IIIB
  J07      33    M     signet--ring   PD      LOWER 1/3    IB
  J08      28    F     signet--ring   PD      MIDDLE 1/3   IB
  J09      36    M     signet--ring   PD      COMBINED     IV
  J10      34    M     tubular        PD      LOWER 1/3    IA
  J11      36    F     tubular        MD      UPPER 1/3    II
  J12      35    F     signet--ring   PD      MIDDLE 1/3   IV
  J13      35    F     tubular        WD      COMBINED     IV
  J14      37    F     signet--ring   PD      MIDDLE 1/3   IIIA
  J15      36    M     signet--ring   PD      MIDDLE 1/3   IA
  J16      31    M     tubular        PD      MIDDLE 1/3   IB
  J17      35    F     signet--ring   PD      UD           II
  J18      28    M     signet--ring   PD      MIDDLE 1/3   UD
  J19      35    F     signet--ring   PD      MIDDLE 1/3   IB
  J20      36    F     signet--ring   PD      MIDDLE 1/3   IV
  J22      26    M     signet--ring   PD      LOWER 1/3    IV
  J23      29    F     signet--ring   PD      UPPER 1/3    IV
  J24      32    F     signet--ring   PD      COMBINED     IA
  J25      33    M     signet--ring   PD      UD           UD
  J26      31    M     tubular        PD      LOWER 1/3    IV
  J27      31    M     tubular        PD      UD           UD
  J28      30    M     tubular        PD      LOWER 1/3    IIIA
  J30      33    F     signet--ring   PD      MIDDLE 1/3   IB
  J31      31    M     signet--ring   PD      UD           IV
  J32      33    F     mucinous       PD      COMBINED     IIIA
  J33      35    M     signet--ring   PD      MIDDLE 1/3   IA
  J34      35    F     tubular        PD      COMBINED     IV
  J35      33    M     signet--ring   PD      LOWER 1/3    IV
  J36      35    F     tubular        MD      MIDDLE 1/3   IV
  J37      19    M     signet--ring   PD      UD           UD
  J38      27    F     tubular        PD      LOWER 1/3    IIIA
  J39      35    F     signet--ring   PD      LOWER 1/3    IIIB
  J40      30    F     tubular        PD      LOWER 1/3    IV
  J41      33    M     signet--rin    WD      COMBINED     IV
  J42      31    F     signet--ring   PD      MIDDLE 1/3   IIIA
  O01      62    F     tubular        PD      MIDDLE 1/3   IA
  O02      62    F     signet--ring   PD      LOWER 1/3    IIIA
  O03      64    F     tubular        PD      LOWER 1/3    II
  O04      60    M     tubular        MD      MIDDLE 1/3   IIIA
  O05      72    M     tubular        MD      LOWER 1/3    UD
  O06      59    M     tubular        MD      LOWER 1/3    II
  O07      59    M     tubular        MD      LOWER 1/3    II
  O08      61    M     tubular        PD      LOWER 1/3    IB
  O09      55    F     tubular        MD      LOWER 1/3    IV
  O10      55    M     tubular        WD      UPPER 1/3    IA
  O11      69    F     tubular        PD      LOWER 1/3    IB
  O12      69    M     tubular        PD      MIDDLE 1/3   IV
  O14      58    F     tubular        WD      LOWER 1/3    II
  O15      65    M     tubular        MD      LOWER 1/3    IIIA
  O16      71    F     tubular        MD      MIDDLE 1/3   IB
  O17      62    F     tubular        MD      LOWER 1/3    IIIA
  O18      50    M     tubular        MD      LOWER 1/3    IIIA
  O19      67    M     tubular        MD      LOWER 1/3    IA
  O20      57    M     tubular        WD      MIDDLE 1/3   IV
  O21      75    F     tubular        MD      COMBINED     II
  O22      60    F     tubular        PD      LOWER 1/33   IIIB
  O23      51    M     tubular        MD      MIDDLE 1/3   IIIB
  O24      58    M     signet--ring   PD      LOWER 1/3    II
  O25      65    M     signet--ring   PD      MIDDLE 1/3   II
  O26      66    F     tubular        MD      UPPER 1/3    IIIA
  O27      86    M     signet--ring   PD      LOWER 1/3    IIIB
  O28      54    M     signet--ring   PD      LOWER 1/3    IA
  O29      50    M     mucinous       MD      COMBINED     II
  O30      74    M     mucinous       MD      LOWER 1/3    II
  O31      55    F     tubular        MD      LOWER 1/3    IIIA
  O32      62    F     signet--ring   PD      UD           UD
  O33      56    M     signet--ring   PD      COMBINED     IB
  O34      50    F     signet--ring   MD      LOWER 1/3    II
  O37      67    F     mucinous       PD      LOWER 1/3    IA
  O38      56    M     mucinous       MD      COMBINED     IV
  O39      68    M     signet--ring   PD      MIDDLE 1/3   IA
  O40      68    M     tubular        WD      MIDDLE 1/3   II

WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated, upper 1/3, cardia and fundus; middle 1/3, body; lower 1/3, pylorus and antrum. UD, undetermined. Combined tumors are located in more than 2 different locations

###### 

Summary of Microsatellite Instability of the Gastric Carcinoma

  No    D2S71   D2S119   D3S1067   D6S87   D8S87   D11S905   RER
  ----- ------- -------- --------- ------- ------- --------- -----
  J01   −       −        −         −       −       −         −
  J02   \+      \+       \+        \+      −       −         \+
  J03   \+      −        \+        \+      −       \+        \+
  J04   −       −        −         −       \+      ND        \+
  J05   −       −        −         −       −       −         −
  J06   −       −        −         −       −       −         −
  J07   −       −        −         −       −       −         −
  J08   −       −        −         −       −       −         −
  J09   −       −        −         −       −       −         −
  J10   −       −        −         −       −       −         −
  J11   −       −        −         −       −       −         −
  J12   −       −        −         −       −       −         −
  J13   ND      −        −         ND      \+      −         \+
  J14   −       −        −         −       −       −         −
  J15   −       −        −         −       −       −         −
  J16   −       −        −         −       −       −         −
  J17   −       −        −         −       −       −         −
  J18   −       −        −         −       −       −         −
  J19   −       −        −         −       −       −         −
  J20   ND      −        −         −       −       −         −
  J22   ND      −        −         −       ND      −         −
  J23   −       −        −         −       ND      −         −
  J24   \+      \+       \+        −       ND      \+        \+
  J25   \+      −        −         \+      \+      −         \+
  J26   −       \+       −         ND      ND      −         \+
  J27   −       −        −         −       −       −         −
  J28   −       −        −         −       ND      −         −
  J30   −       −        −         −       −       −         −
  J31   −       −        −         −       −       −         −
  J32   −       −        −         −       ND      −         −
  J33   −       −        −         −       −       −         −
  J34   −       −        −         −       −       −         −
  J35   −       −        −         −       ND      −         \+
  J36   \+      −        \+        \+      −       −         −
  J37   −       −        −         −       −       −         \+
  J38   \+      −        −         −       −       −         −
  J39   −       −        −         −       −       −         −
  J40   −       −        −         −       −       −         −
  J41   −       −        −         −       −       −         −
  J42   −       −        −         ND      −       ND        −
  O01   −       −        −         −       −       −         −
  O02   −       −        \+        ND      \+      ND        \+
  O03   −       −        −         −       −       −         −
  O04   −       −        \+        −       −       −         \+
  O05   −       −        −         −       −       −         −
  O06   −       −        −         −       −       ND        −
  O07   −       −        −         −       −       −         −
  O08   −       ND       −         −       −       ND        −
  O09   −       ND       −         −       −       ND        −
  O10   −       −        −         −       −       −         −
  O11   −       \+       −         ND      \+      ND        \+
  O12   −       ND       −         ND      −       ND        −
  O14   −       ND       −         −       −       ND        −
  O15   −       −        \+        −       −       −         \+
  O16   −       −        −         −       −       −         −
  O17   \+      \+       −         \+      −       −         \+
  O18   −       −        −         ND      −       −         −
  O19   −       −        −         −       −       −         −
  O20   −       ND       −         −       −       ND        −
  O21   −       ND       −         −       −       −         −
  O22   −       ND       −         −       −       ND        −
  O23   −       −        −         −       −       −         −
  O24   −       ND       −         −       −       −         −
  O25   −       −        −         −       −       −         −
  O26   −       ND       −         −       −       −         −
  O27   −       ND       −         −       −       ND        −
  O28   −       −        −         −       −       −         −
  O29   −       −        −         −       −       −         −
  O30   −       −        ND        −       −       \+        \+
  O31   \+      −        −         −       −       −         \+
  O32   \+      −        −         −       −       −         \+
  O33   −       ND       −         ND      −       ND        −
  O34   −       ND       −         ND      −       ND        −
  O37   −       −        −         −       −       ND        −
  O38   −       −        −         −       −       −         −
  O39   −       ND       −         ND      −       ND        −
  O40   −       −        −         −       −       −         −

\+ : positive for MI, −: negatiVe for MI, NO: not done

###### 

Frequency of RER-positive and Negative Phenotypes in Young and Elderly Gastric Adenocarcinoma Patients

  Categories   RER phenotype                   
  ------------ --------------- --------------- ---------------
  Young        51.9% (40/77)   22.5% (9/40)    77.5% (31/40)
  Elderly      48.1% (37/77)   21.6% (8/37)    78.4% (29/37)
  Total        100% (77/77)    22.1% (17/77)   77.9% (60/77)

Number of subgroup cases/number of total cases.

Number of RER-positive cases/number of subgroup cases.

Number of RER-negative cases/number of subgroup cases

###### 

Frequency of RER-positive and Negative Phenotypes in Male and Female Gastric Adenocarcinoma Patients

  Categories   RER phenotype                   
  ------------ --------------- --------------- ---------------
  Male         54.5% (42/77)   16.7% (7/42)    83.3% (35/42)
  Female       45.5% (35/77)   28.6% (10/35)   71.4% (25/35)
  Total        100% (77/77)    22.1% (17/77)   77.9% (60/77)

Number of subgroup cases/number of total cases.

Number of RER-positive cases/number of subgroup cases.

Number of RER-negative cases/number of subgroup cases.

###### 

Frequency of RER-positive and Negative Phenotypes According to the Histologic Types of Gastric Adenocarcinoma Patients

  Categories     RER phenotype                   
  -------------- --------------- --------------- ---------------
  Tubular        46.8% (36/77)   27.8% (10/36)   72.2% (26/36)
  Signet--ring   46.8% (36/77)   16.7% (6/36)    83.3% (30/36)
  Mucinous       6.5% (5/77)     20.0% (1/5)     80.0% (4/5)
  Total          100% (77/77)    22.1% (17/77)   77.9% (60/77)

Number of subgroup cases/number of total cases.

Number of RER-positive cases/number of subgroup cases.

Number of RER-negative cases/number of subgroup cases.

###### 

Frequency of RER-positive and Negative Phenotypes According to the Differentiation of Gastric Adenocarcinoma Patients

  Categories   RER phenotype                                                                      
  ------------ --------------- ------------------------------------------------------------------ ---------------
  WD           7.8% (6/77)     16.7% (1/6)                                                        83.3% (5/6)
  MD           27.3% (21/77)   28.6% (10/35)[^\*^](#tfn16-kjim-12-2-144-5){ref-type="table-fn"}   71.4% (15/21)
  PD           61.9% (50/77)   20.0% (10/50)                                                      80.0% (40/50)
  Total        100% (77/77)    22.1% (17/77)                                                      77.9% (60/77)

Number of subgroup cases/number of total cases.

Number of RER-positive cases/number of subgroup cases.

Number of RER-negative cases/number of subgroup cases.

WD, well differentiated adenocarcinoma; MD, moderately differentiated adenocarcinoma; PD, poorly differentiated adenocarcinoma.

Statistically different (higher ratio) than WD (p\<0.001).

###### 

Frequency of RER-positive and Negative Phenotypes According to the Location of Gastric Adenocarcinoma

  Categories     RER phenotype                                                                     
  -------------- --------------- ----------------------------------------------------------------- ---------------
  Upper third    6.8% (4/59)     0% (0/4)                                                          100% (4/4)
  Middle third   42.4% (25/59)   16.0% (4/25)[^\*^](#tfn21-kjim-12-2-144-5){ref-type="table-fn"}   84.0% (21/25)
  Lower third    50.8% (30/59)   26.7% (8/30)[^\*^](#tfn21-kjim-12-2-144-5){ref-type="table-fn"}   73.3% (22/30)
  Total          100% (77/77)    20.3% (12/59)                                                     79.7% (47/59)

Number of subgroup cases/number of total cases.

Number of RER-positive cases/number of subgroup cases.

Number of RER-negative cases/number of subgroup cases.

Upper third, cardia and fundus; middle third, body; lower third, antrum and pylorus.

Statistically different (higher) ratio than that of upper third (p\< 0.001).

###### 

Frequency of RER-positive and Negative Phenotypes According to the Stages of Gastric Adenocarcinoma

  Categories   RER phenotype                   
  ------------ --------------- --------------- ---------------
  IA           18.3% (13/71)   15.4% (2/13)    84.6% (11/13)
  IB           12.6% (9/71)    11.1% (1/9)     88.9% (8/9)
  II           18.3% (13/71)   7.7% (1/13)     92.3% (12/13)
  IIIA         18.3% (13/71)   53.8% (7/13)    46.2% (6/13)
  IIIB         7.0% (5/71)     0% (0/5)        100% (5/5)
  IV           25.4% (18/71)   22.2% (4/18)    77.8% (14/18)
  Total        100% (71/71)    21.1% (15/71)   78.9% (56/71)

Number of subgroup cases/number of total cases.

Number of RER-positive cases/number of subgroup cases.

Number of RER-negative cases/number of subgroup cases.
